An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
An estimated 102 million Americans have cholesterol levels that are considered borderline high-risk.1 This staggering fact makes lowering cholesterol one of the most imperative things to do to promote overall heart health. Unfortunately, too few people understand the essential steps in reaching this goal. Metamucil and Dr. Michael Roizen, Chairman of the Wellness Institute at Cleveland Clinic and host of the upcoming PBS series, “Younger You,” have joined to present the “Five Things Every American Needs to Do to Lower Their Cholesterol” to encourage Americans to lead a proactive lifestyle with small modifications and dietary changes.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/metamucil/48409/
To help Americans determine their risk for chronic diseases and get them on a path to better health, CVS/pharmacy announced today the launch of the 2011 “To Your Health” program, offering free preventive health screenings at more than 800 events in communities across the country. The program will get underway in Houston on Saturday, March 5th, and continue in Dallas, Los Angeles, Washington D.C., Atlanta, Philadelphia, Chicago and Miami.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/cvs/48303/
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s antibacterial drug DIFICID™ (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and is beginning to emerge in the community among people previously at low risk for the disease. In the largest Phase 3 clinical studies ever conducted in CDAD, DIFICID had clinical response rates at the end of treatment that were non-inferior to oral vancomycin. DIFICID was superior to vancomycin in sustaining clinical response through 25 days beyond the end of treatment. DIFICID is the only FDA-approved antibacterial drug proven to be superior to vancomycin in sustained clinical response for CDAD.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/optimerpharma/50177/
Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ:AMGN) today launch Act 2 Reduce Fractures™, an educational campaign for women with postmenopausal osteoporosis at increased risk for fractures. Earlier this year, Danner was diagnosed with postmenopausal osteoporosis at increased risk for fractures and wants to encourage women like her to educate themselves, take action and speak to their doctors to learn all they can about helping to strengthen their bones. The campaign is being supported by American Bone Health, the Global Healthy Living Foundation and the Older Women’s League.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/amgen/48052/
Pregnancy is an exciting time filled with hopeful anticipation, and most pregnancies are uneventful and result in healthy babies. Pregnancy, however, is not entirely without risk, leading some expectant parents to worry about birth defects and whether they’ll give birth to a healthy baby.
Many birth defects are minor and easily treated. But about one in every 33 babies is born with a major birth defect, according to the Centers for Disease Control. Major birth defects may have a serious impact on development, functional ability and overall health. Throughout January, which is Birth Defects Prevention Month, BeSmartBeWell.com highlights pregnancy risks and preventable birth defects. At BeSmartBeWell.com medical experts, and real-life expectant moms, like Sharon, share information to help lower the risk for birth defects.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/birthdefects/50829/
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
As global organizations grapple with a more technologically intensive and complex agenda, fissures in traditional approaches to talent management and leadership development are increasingly visible. This was a key theme that emerged at ON Talent, an invitation-only discussion hosted at Deloitte University where leading names in talent argued that the prevailing models of talent development no longer hold. New models like the corporate lattice that are better attuned to the times must be adopted or the risk of HR becoming less relevant is high.
“The system is broken,” said Annmarie Neal, founder of the Center for Leadership Innovation. “If the economic models of the last era of business won’t translate to today’s environment, why would our organizational and talent models translate? In fact, the way we have traditionally approached talent can be an impediment in the 21st century.
Adults over the age of 60 are at the greatest risk of atrial fibrillation (AF), a potentially life-threatening heart rhythm disorder. Yet, according to a recent survey conducted by the Heart Rhythm Society (HRS), more than 25 percent of Americans between the ages of 55 and 64 have never heard of AF. Today marks the kick-off of HRS’ second annual “A-Fib Feels Like” campaign to help educate Americans about the symptoms and warning signs associated with AF and encourage those who suffer from the disorder to talk to their doctors about their risks and potential treatment options.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57735-a-fib-feels-like-campaign-warning-signs-atrial-fibrillation
During the third quarter, we were again able to capture the benefits of AEGON’s strategic priorities, resulting in solid earnings growth, improved profitability of sales, lower expenses and a continued strong capital position. Our franchise remains healthy, as evidenced by the particularly high level of At-Retirement and pension sales. At the same time, we are making essential investments to reshape our businesses in both our established and developing markets to respond effectively to the changing conditions and new realities. Although there are signs of gradually improving market conditions, there remains considerable uncertainty in the general economic environment. Consequently, we believe it is prudent and necessary to maintain a sufficient financial buffer while at the same time adhering to our strict risk and pricing discipline. The steps we are taking across our organization to get closer to our end customers, combined with the strength of our current position, give us full confidence in the prospects for our business going forward.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58637-aegon-quarter-3-results
Admittedly, there’s a risk in any course we follow other than this, but every lesson of history tells us that the greater risk lies in appeasement, and this is the specter our well-meaning liberal friends refuse to face—that their policy of accommodation is appeasement, and it gives no choice between peace and war, only between fight or surrender. If we continue to accommodate, continue to back and retreat, eventually we have to face the final demand—the ultimatum. And what then—when Nikita Khrushchev has told his people he knows what our answer will be? He has told them that we’re retreating under the pressure of the Cold War, and someday when the time comes to deliver the final ultimatum, our surrender will be voluntary, because by that time we will have been weakened from within spiritually, morally, and economically. He believes this because from our side he’s heard voices pleading for “peace at any price” or “better Red than dead,” or as one commentator put it, he’d rather “live on his knees than die on his feet.” And therein lies the road to war, because those voices don’t speak for the rest of us.
You and I know and do not believe that life is so dear and peace so sweet as to be purchased at the price of chains and slavery. If nothing in life is worth dying for, when did this begin—just in the face of this enemy? Or should Moses have told the children of Israel to live in slavery under the pharaohs? Should Christ have refused the cross? Should the patriots at Concord Bridge have thrown down their guns and refused to fire the shot heard ’round the world? The martyrs of history were not fools, and our honored dead who gave their lives to stop the advance of the Nazis didn’t die in vain. Where, then, is the road to peace? Well it’s a simple answer after all.
You and I have the courage to say to our enemies, “There is a price we will not pay.” “There is a point beyond which they must not advance.” Winston Churchill said, “The destiny of man is not measured by material computations. When great forces are on the move in the world, we learn we’re spirits—not animals.” And he said, “There’s something going on in time and space, and beyond time and space, which, whether we like it or not, spells duty.”
You and I have a rendezvous with destiny.
We’ll preserve for our children this, the last best hope of man on earth, or we’ll sentence them to take the last step into a thousand years of darkness.”
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
